A pioneering research initiative at the University of Arizona is set to revolutionize non-invasive biomedical imaging by securing nearly $2.7 million in funding from the National Institutes of Health (NIH) Common Fund Venture Program. Spearheaded by Florian Willomitzer from the James C. Wyant College of Optical Sciences and Dr. Clara Curiel-Lewandrowski from the U of A Comprehensive Cancer Center, this cutting-edge project focuses on advancing synthetic wavelength imaging (SWI) to enable deeper, higher-contrast visualization of biological tissues, particularly targeting non-melanoma skin cancers.
The NIH’s select funding through the “Advancing Non-Invasive Optical Imaging Approaches for Biological Systems” initiative places the U of A team among a handful of elite groups nationwide striving to overcome the formidable challenges of imaging inside living organisms. The project’s ultimate aim is to develop portable, tunable imaging technologies that push beyond the prevailing resolution-depth-contrast trade-offs faced by current optical modalities, thus enabling novel clinical insights and therapeutic monitoring.
Central to the team’s work is synthetic wavelength imaging, an optical innovation that synthesizes a virtual imaging wavelength from two distinct real illumination wavelengths. This synthetic wavelength is notably longer, granting the system enhanced resilience to light scattering within tissue—a critical limitation for traditional visible and near-infrared optical imaging methods. Unlike conventional approaches such as confocal microscopy or optical coherence tomography, which achieve exquisite detail at shallow depths but falter as scattering intensifies, SWI holds the promise of acquiring clear, high-contrast images at substantially greater tissue penetration.
Willomitzer emphasizes that their technology uniquely balances penetration depth with high spatial resolution and enhanced contrast by leveraging the computational fusion of information contained within the original optical carriers. This synergy enables visualization of skin cancers such as basal cell carcinoma and squamous cell carcinoma at depths previously unattainable with solely optical methods. These cancer types represent a significant burden worldwide and are known for their variable invasion patterns, posing substantial diagnostic and treatment challenges.
Dr. Curiel-Lewandrowski highlights the urgent clinical need addressed by this technology, noting that current imaging systems lack the versatility to accurately detect tumor margins or monitor responses to treatment across the spectrum of lesion sizes and depths encountered in non-melanoma skin cancers. The development of a tunable imaging platform affords the potential to customize parameters for maximum diagnostic yield, ensuring the reliability and repeatability paramount for both initial detection and longitudinal surveillance.
The research team is constructing a prototype laboratory bench apparatus designed to eventually translate into a portable clinical device, facilitating the first in vivo human studies. By combining optical instrumentation precision with advanced computational algorithms, the project aims to produce highly detailed images capable of distinguishing cellular and subcellular features within living tissues. This opens new avenues not only for skin cancer diagnosis but potentially for other applications requiring deep tissue visualization through highly scattering media.
Current alternatives such as ultrasound and hybrid imaging modalities can probe deeper anatomical layers but often sacrifice resolution or suffer from insufficient contrast specificity when characterizing certain tumor types. The synthetic wavelength approach promises to bridge this gap by providing a window into morphological and functional tissue changes non-invasively and with real-time capability.
Beyond oncology, Willomitzer envisions extensive biomedical implications arising from the adaptability of synthetic wavelength imaging. The methodology’s flexibility in wavelength tuning could enable breakthroughs in neuroimaging and breast cancer diagnostics, where penetrating dense, scattering tissues remains a significant hurdle to current imaging standards.
The project brings together a multidisciplinary team, including experts in optical sciences, biomedical engineering, pharmacology, and dermatology. This collaboration reflects a growing trend where integration of health sciences with engineering and computational optics accelerates the development of next-generation diagnostic technologies.
The NIH initiative driving this work aims to enable high-speed, non-invasive imaging that captures rapid biological phenomena such as muscle contractions and blood flow, in addition to static cellular architecture. Achieving such capabilities would revolutionize early disease detection, personalized treatment planning, and overall patient management, reducing reliance on invasive surgical procedures.
As the prototype progresses towards clinical validation, the research team remains optimistic about translating these advances into practical tools that will empower clinicians to assess tumor boundaries with unprecedented precision, enabling tailored therapeutic interventions and improved patient outcomes. Success in this endeavor could usher in a new era of optical imaging where limitations imposed by light scattering, resolution, and contrast are effectively surmounted.
By harnessing synthetic wavelength imaging’s unparalleled resistance to scattering combined with sophisticated computational analyses, the University of Arizona group is poised to make a significant leap forward. Their work exemplifies the transformative potential at the intersection of photonics, computation, and medicine, promising to reshape how clinicians visualize and treat cancer and possibly other complex diseases hidden beneath the skin’s surface.
Subject of Research: Development of synthetic wavelength-based non-invasive optical imaging technologies for deep tissue visualization in skin cancer diagnostics.
Article Title: University of Arizona Receives NIH Funding to Advance Synthetic Wavelength Imaging for Non-Melanoma Skin Cancer Diagnosis
Web References:
NIH Common Fund Venture Program: https://commonfund.nih.gov/venture
James C. Wyant College of Optical Sciences: https://www.optics.arizona.edu/
U of A Comprehensive Cancer Center: http://cancercenter.arizona.edu/
Advancing Non-Invasive Optical Imaging Approaches: https://commonfund.nih.gov/venture/nioi
Biomedical Engineering at U of A: https://bme.engineering.arizona.edu/
Image Credits: Parker Liu, University of Arizona
Keywords: synthetic wavelength imaging, SWI, non-melanoma skin cancer, non-invasive imaging, optical imaging, light scattering, skin cancer diagnostics, biomedical imaging, deep tissue imaging, NIH Common Fund, computational optics, tumor margin detection
Tags: advanced optical modalitiesbiomedical imaging advancementsclinical therapeutic monitoringlight scattering in tissuesNIH funding for cancer researchnon-invasive imaging technologynon-melanoma skin cancersoptical imaging innovationsportable imaging technologiesskin cancer diagnosissynthetic wavelength imagingUniversity of Arizona research
